Intravenous (IV) Iron Drugs

World Market Report

MCP-6464

EXECUTIVE ENGAGEMENTS

POOL

463
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

93
Interactions with Platform & by Email

PARTICIPANTS

19
Unique # Participated

VALIDATIONS

8
Responses Validated*

COMPANIES

33
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2023

TABLES

214

PAGES

354

EDITION

16

PRICE

USD 5600

CODE

MCP-6464


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

RANK

(S/A/N/T)

%

VALIDATED RESEARCH *

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Intravenous (IV) Iron Drugs Market to Reach $4.8 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Intravenous (IV) Iron Drugs estimated at US$2.7 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2022-2030. Ferric Carboxymaltose, one of the segments analyzed in the report, is projected to record a 7.7% CAGR and reach US$2.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Iron Dextran segment is readjusted to a revised 6.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $949.1 Million, While China is Forecast to Grow at 10.8% CAGR
The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$949.1 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$658.4 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 6.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$550.2 Million by the year 2030.

SELECT PLAYERS

AbbVie Inc (AbbVie); Akebia Therapeutics, Inc.; American Regent, Inc. ; Covis Pharma GmbH.; Daiichi Sankyo Company, Ltd.; Galenica Group; Iron4u Aps; NIPPON SHINYAKU CO., LTD.; Pharmacosmos A/S; Rockwell Medical, Inc.; Sanofi S.A. ; Shield Therapeutics Plc; Vifor Pharma Management Ltd.

SEGMENTS

» Product Type (Ferric Carboxymaltose, Iron Dextran, Iron Sucrose, Other Product Types) » Application (Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease, Other Applications)

GEOGRAPHIES

» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » Australia » India » South Korea » Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » UAE » Rest of Middle East » Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Iron Deficiency Anemia (IDA) – A Major Global Health Concern
EXHIBIT: Iron Deficiency Prevalence by Disease: Analyzed by Percentage Number of Patients with ID and IDA in CKD (with dialysis), Non-Dialysis-CKD, Congestive Heart Failure, Chemotherapy Induced Anemia, Irritable Bowel Disease, Patient Blood Management (Surgery), Heavy Uterine Bleeding and Postpartum (OB-GYN)
Impact of Covid-19 and Global Economic Update
War & Inflation Supersede COVID-19 as Major Downside Risks for the Global Economy in 2023 & Beyond
Here’s How Inflationary Pressures Affect the Economy
Competitive Landscape
Intravenous (IV) Iron Drugs – Global Key Competitors Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for 33 Players Worldwide in 2023 (E)
Global Market Overview and Prospects
Global Intravenous Iron Drugs Market Driven by Rising Incidence of CKD and Cancer
Ferric CarboxyMaltose Dominates the Global Intravenous Iron Drugs Market
CKD Leads the Application Segment, Cancer Expected to Witness Fastest Growth
North America and Europe Hold Major Share, Asia-Pacific Witnesses Rapid Growth
Low- and Mid-income Countries Present Lucrative Penetration Opportunities for IV Iron Drugs
Leading Intravenous Iron Drugs Globally
Leading IV Iron Drugs Available in the Market
Leading Intravenous Iron Drugs: In a Nutshell
Ferinject/Injectafer – The Leading Intravenous Iron Drug Globally
Venofer®
Feraheme
Gluconate (Ferrlecit® and Nulecit)
Dextran
Monoferric
Triferic AVNU
INFeD
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Expanding Pool of ESRD and CKD Patients – The Major Growth Driver for Intravenous (Iv) Iron Drugs
EXHIBIT: ESRD Prevalence Worldwide: Number of Treated ESRD Patients Per Million Population in Select Countries for 2019
EXHIBIT 3: Global Population of Kidney Disease Patients Undergoing Treatment by Type of Modality (2019 and 2022P): Percentage Breakdown of Patients Undergoing Dialysis Therapy and Kidney Transplantation
Dialysis Patients – A Major Market for Intravenous Iron Supplements
EXHIBIT: Global Dialysis Patient Population Breakdown by Geographic Region/Country (2019 and 2024)
EXHIBIT: Global Dialysis Patient Population Distribution by Modality for Select Countries (2016): Percentage Breakdown of Hemodialysis (HD) and Peritoneal Dialysis (PD) Patients
Ageing Population Drives Demand for IV Iron Drugs
EXHIBIT: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
EXHIBIT: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Rising Incidence of Cancer and the Associated Anemia Drives the Demand for Intravenous Iron Drugs
EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT: Breakdown of Total Number of Cancer Cases by Region: 2020
EXHIBIT: Breakdown of Total Number of Cancer Cases by Type: 2020
Rising Incidence of Diabetes to Propel the Market for Intravenous Iron Drugs
EXHIBIT: World Diabetes and Population Statistics (2019, 2030 & 2045)
EXHIBIT 15: Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030, and 2045
Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market
EXHIBIT: Healthcare Expenditure as a % of GDP by Region for 2019
Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
Comparison of Ferrous Salts with IV Iron Therapy
2020: Pharmacosmos Receives FDA Approval for Single Dose Infusion of Ferric Derisomaltose in IDA Patients
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
New Study Demonstrates IV Iron to Improve Long-term Outcomes in Heart Failure Patients
EXHIBIT: Incidence of Heart Failure (In 000s) in the U.S. by Gender for the Year 2022
Correction of IDA in Pregnancy Signals Opportunities
Women’s Health – A Key Growth Opportunity
Perioperative and Postoperative Anemia – A Niche Market Beckons
Adverse Reactions of IV Iron Preparations Raise Concerns
Dosing Limitations Plague IV Iron Market
Select Therapeutic Areas and the Required Iron Doses
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Ferric Carboxymaltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
World Historic Review for Ferric Carboxymaltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Ferric Carboxymaltose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Iron Dextran by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
World Historic Review for Iron Dextran by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Iron Dextran by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
World Historic Review for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Iron Sucrose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
World Historic Review for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Chronic Kidney Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
World Intravenous (IV) Iron Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
World Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
UNITED STATES
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
USA Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
USA Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
USA 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
USA Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
USA Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
USA 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
CANADA
Canada Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Canada Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Canada 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Canada Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Canada Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Canada 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
JAPAN
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Japan Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Japan Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Japan 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Japan Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Japan Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Japan 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
CHINA
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
China Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
China Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
China 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
China Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
China Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
China 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
EUROPE
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
Europe Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
FRANCE
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
France Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
France Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
France 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
France Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
France Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
France 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
GERMANY
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Germany Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Germany Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Germany 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Germany Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Germany Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Germany 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
ITALY
Italy Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Italy Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Italy 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Italy Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Italy Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Italy 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
UNITED KINGDOM
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
UK Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
UK Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
UK 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
UK Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
UK Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
UK 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
SPAIN
Spain Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Spain Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Spain 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Spain Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Spain Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Spain 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
RUSSIA
Russia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Russia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Russia 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Russia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Russia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Russia 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Rest of Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Rest of Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Rest of Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
ASIA-PACIFIC
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
AUSTRALIA
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
Australia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Australia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Australia 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Australia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Australia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Australia 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
INDIA
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
India Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
India Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
India 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
India Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
India Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
India 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
SOUTH KOREA
South Korea Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
South Korea Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
South Korea 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
South Korea Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
South Korea Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
South Korea 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Rest of Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Rest of Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
LATIN AMERICA
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
Latin America Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
ARGENTINA
Argentina Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Argentina Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Argentina 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Argentina Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Argentina Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Argentina 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
BRAZIL
Brazil Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Brazil Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Brazil 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Brazil Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Brazil Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Brazil 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
MEXICO
Mexico Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Mexico Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Mexico 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Mexico Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Mexico Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Mexico 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
REST OF LATIN AMERICA
Rest of Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Rest of Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Rest of Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Rest of Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
MIDDLE EAST
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
Middle East Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
IRAN
Iran Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Iran Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Iran 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Iran Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Iran Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Iran 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
ISRAEL
Israel Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Israel Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Israel 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Israel Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Israel Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Israel 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
SAUDI ARABIA
Saudi Arabia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Saudi Arabia 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Saudi Arabia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Saudi Arabia 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
UNITED ARAB EMIRATES
UAE Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
UAE Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
UAE 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
UAE Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
UAE Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
UAE 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
REST OF MIDDLE EAST
Rest of Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Rest of Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Rest of Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Rest of Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
AFRICA
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Africa Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Africa Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Africa 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
Africa Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
Africa Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Africa 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com